Edition:
United States

Allergan plc (AGN)

AGN on New York Consolidated

254.16USD
27 Jul 2017
Change (% chg)

-- (--)
Prev Close
$254.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,185,635
52-wk High
$261.27
52-wk Low
$184.50

Latest Key Developments (Source: Significant Developments)

Allergan submits investigational NDA for rtgel in combination with botox
Wednesday, 19 Jul 2017 08:30am EDT 

July 19 (Reuters) - Urogen Pharma Ltd ::Investigational new drug application for rtgel™ in combination with botox® for the treatment of overactive bladder submitted to FDA by Allergan.Says it will receive a milestone payment of $7.5 million under its exclusive worldwide licensing agreement with allergan.Urogen Pharma - milestone payment resulting from Allergan's submission of investigational new drug application for rtgel in combination with botox to U.S. FDA.  Full Article

Amgen, Allergan to discuss data supporting biologics license application for ABP 215
Thursday, 13 Jul 2017 08:00am EDT 

July 13 (Reuters) - Allergan Plc :Amgen and allergan to discuss data supporting biologics license application for abp 215, a biosimilar candidate to avastin® (bevacizumab).Amgen inc- ‍fda has set a biosimilar user fee act (bsufa) target action date of sept. 14, 2017, for abp 215​.Amgen inc- ‍co, allergan will discuss data supporting abp 215 bla with oncologic drugs advisory committee of u.s. fda​.  Full Article

Allergan announces launch of artificial tear refresh optive mega-3
Tuesday, 27 Jun 2017 08:00am EDT 

June 27 (Reuters) - Allergan Plc ::Allergan plc - announced launch of over-the-counter artificial tear refresh optive mega-3.  Full Article

Allergan to acquire Keller Medical, adding Keller Funnel to co's leading plastic surgery portfolio
Wednesday, 7 Jun 2017 08:30am EDT 

June 7 (Reuters) - Allergan Plc :Allergan to acquire Keller Medical, Inc., adding Keller Funnel® to company's leading plastic surgery portfolio.  Full Article

Allergan announces closing of public offering
Friday, 26 May 2017 07:00am EDT 

May 26 (Reuters) - Allergan Plc ::Allergan announces closing of public offering of senior notes to refinance existing debt.  Full Article

Allergan prices public offering of senior notes to refinance existing debt
Tuesday, 23 May 2017 05:30pm EDT 

May 23 (Reuters) - Allergan Plc :Allergan announces pricing of public offering of senior notes to refinance existing debt.Allergan plc - has priced an offering of eur 2.7 billion aggregate principal amount of senior unsecured notes in 4 tranches.Allergan plc - notes will be issued by its indirect wholly-owned subsidiary, allergan funding scs.  Full Article

Carl Icahn dissolves shared share stake in Allergan
Monday, 15 May 2017 05:59pm EDT 

May 15 (Reuters) - Carl Icahn::Carl Icahn dissolves share stake in Allergan Plc - sec filing.Carl Icahn takes shared share stake of 10.6 million shares in Welbilt Inc.Carl Icahn holdings cited is Icahn's shared share stake in the respective companies.Carl Icahn - change in holdings are as of March 31, 2017 and compared with the previous quarter ended as of Dec 31, 2016.  Full Article

Appaloosa LP takes share stake in CBS, cuts in Allergan
Friday, 12 May 2017 04:30pm EDT 

May 12 (Reuters) - Appaloosa LP:Appaloosa lp takes share stake of 1.0 million of class b shares in cbs corp.Appaloosa lp cuts share stake in allergan plc by 31.1 percent to 2.9 million.Appaloosa lp - change in holdings are as of march 31, 2017 and compared with the previous quarter ended as of dec 31, 2016.  Full Article

Allergan announces proposed public offering of senior notes to refinance existing debt
Wednesday, 10 May 2017 03:00am EDT 

May 10 (Reuters) - Allergan Plc :Allergan announces proposed public offering of senior notes to refinance existing debt.Expects to commence an offering of euro-denominated senior unsecured notes in multiple tranches in coming weeks.Allergan - will be allergan's debut bond issuance in euro bond market and is intended to be an economic hedge of company's increasing euro revenues.  Full Article

Allergan reports qtrly loss per share from continuing operations of $7.85
Tuesday, 9 May 2017 07:00am EDT 

May 9 (Reuters) - Allergan Plc ::Allergan reports solid start to 2017 with 5 pct increase in first quarter GAAP net revenues to $3.6 billion.Q1 non-GAAP earnings per share $3.35 .Q1 revenue $3.6 billion versus I/B/E/S view $3.54 billion.Qtrly loss per share from continuing operations $7.85.Sees FY total net revenues $15,800 – $16,000 million.Company raises full year 2017 guidance.Sees FY net loss per share $9.70 - $10.20.Sees FY research and development expense to be about $2.1 billion.Sees 2017 non-GAAP net income per share $15.85 - $16.35.FY2017 earnings per share view $16.05, revenue view $15.73 billion -- Thomson Reuters I/B/E/S.Q1 earnings per share view $3.30 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-U.S. Senator Claire McCaskill opioid investigation expands to include distributors and additional manufacturers‍​

* U.S. Senator Claire McCaskill opioid investigation expands to include distributors and additional manufacturers‍​